A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)

Tara L Lin,Matthew J Wieduwilt,Laura F Newell,Gary J Schiller,S Eric Rubenstein,Wendy Stock,Erica Warlick,Dale L Bixby,Nikolai Podoltsev,Qi An,Stefan Faderl,Arthur C Louie,Geoffrey L Uy

doi:10.1016/j.clml.2018.07.063

A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)

Tara L Lin, Matthew J Wieduwilt + Show 11 more

Open Access

https://doi.org/10.1016/j.clml.2018.07.063

Copy DOI

Journal: Clinical Lymphoma Myeloma and Leukemia	Publication Date: Aug 28, 2018
License type: cc-by-nc-nd

Affiliation: University of Kansas, University of California, San Diego, Oregon Health & Science University, University of California, Los Angeles, Franciscan Health Indianapolis, University of Chicago, University of Minnesota System, University of Michigan–Ann Arbor, Yale University, Jazz Pharmaceuticals (United States), University of Washington

#Refractory Anemia With Excess Of Blasts In Transformation #Blasts In Transformation + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.